Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies
Sign Up to like & getrecommendations! Published in 2022 at "Advances in Therapy"
DOI: 10.1007/s12325-021-02024-x
Abstract: Biologic therapeutics can trigger immune responses in patients. As part of the totality of evidence that is required for regulatory approval of biosimilars, immunogenicity similarity must be assessed in the clinical programs. Pegfilgrastim-cbqv (UDENYCA®) is… read more here.
Keywords: immunogenicity pegfilgrastim; immunogenicity; pegfilgrastim; pegfilgrastim cbqv ... See more keywords